A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF DARBEPOETIN ALFA ADMINISTERED AT 500 μG ONCE-EVERY-3-WEEKS IN ANEMIC SUBJECTS WITH ADVANCED STAGE NON-SMALL CELL LUNG CANCER RECEIVING MULTI-CYCLE CHEMOTHERAPY.

Authors
Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2016
This article has no abstract
Epistemonikos ID: acf76d6d398a7dc2573ca7ebe9a17079d0f614f3
First added on: Apr 16, 2025